Replies to post #409967 on Amarin Corp Plc (AMRN)

[Tatsumaki]

Nothing to do with manufacturing or sourcing. China simply rewards development of APIs that are filed and approved first in China with longer exclusivity and penalizes drugs already approved in other countries before coming to China. As of today, that clock is ticking. Meaning, with approval of the >500 label, a year needed to negotiate government pricing, still pending approval of a CVD label, the exclusive selling window could be quite short. Theyre essentially are doing what Amarin did in the US. Burn up exclusivity on the "easy" label while waiting for the CVD indication.